Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
ESMO Open
|
April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial
G Schepisi, M Urbini, C Casadei, et al.
Gynecologic Oncology
|
May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
I Vergote, E Van Nieuwenhuysen, A Casado, et al.
ESMO Open
|
February 26, 2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
L Paracchini, A Velle, P Di Gennaro, et al.
ESMO Open
|
December 6, 2025
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
M Bartoletti, A Passarelli, A Fagotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
G Rosati, G Ambrosini, S Barni, et al.
ESMO Open
|
January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
B Pellegrino, E D Capoluongo, M Bagnoli, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
Current Pharmaceutical Design
|
April 12, 2002
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial
F Perrone, C Gallo, B Daniele, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
ESMO Open
|
April 25, 2025
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial
G Schepisi, M Urbini, C Casadei, et al.
Gynecologic Oncology
|
May 11, 2023
Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer
I Vergote, E Van Nieuwenhuysen, A Casado, et al.
ESMO Open
|
February 26, 2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
L Paracchini, A Velle, P Di Gennaro, et al.
ESMO Open
|
December 6, 2025
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
M Bartoletti, A Passarelli, A Fagotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma
G Rosati, G Ambrosini, S Barni, et al.
ESMO Open
|
January 4, 2025
Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial
B Pellegrino, E D Capoluongo, M Bagnoli, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
Current Pharmaceutical Design
|
April 12, 2002
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial
F Perrone, C Gallo, B Daniele, et al.
Page
of 12